SAVER reports no contralateral nodal failures with reduced elective volumes in HPV-positive oropharyngeal cancer

Among 52 HPV-positive oropharyngeal cancer patients, SAVER observed no contralateral nodal failures at median 31 months while reducing parotid dose.

KEY POINTS

  • SAVER was a multisite, single-arm phase II trial evaluating selective avoidance of low-risk elective nodal volumes in patients with p16-positive oropharyngeal squamous cell carcinoma. Fifty-three patients were enrolled between March 2021 and June 2023, of whom 52 received treatment: 36 underwent definitive (chemo)radiotherapy and 16 received postoperative radiation following transoral robotic surgery (TORS). All had a clinically uninvolved contralateral neck but risk factors warranting bilateral elective irradiation. Median follow-up was 31 months, with 41 patients completing the 24-month assessment.
  • Patients were selected for clinically meaningful contralateral nodal risk rather than uniformly favorable disease. Multiple or bulky ipsilateral lymphadenopathy was present in 35/52 patients (67.3%), smoking history exceeded ten pack-years in 18 (34.6%), and 15 (28.8%) met Ang intermediate-risk criteria. Definitive prescriptions included 69.96 Gy in 33 fractions to gross disease, 60 Gy to high-risk ipsilateral regions, and 52.8 Gy to the SAVER elective CTV. Postoperative treatment delivered 54 Gy in 30 fractions to the operative bed and ipsilateral neck, up to 63 Gy for positive margins or extranodal extension, and 51 Gy to the SAVER volume.
  • The SAVER approach selectively reduced the superior, posterior, and lateral extent of the contralateral nodal CTV. Compared with consensus level II–III volumes, the superior border was placed 5 mm below the cranial edge of C2, the lateral border was limited to the medial sternocleidomastoid muscle, and the posterior border extended 5 mm behind the internal jugular vein at level II and 10 mm at level III. The underlying atlas had previously demonstrated an approximately 60% reduction in elective volume, largely by excluding superior level II, much of level IIb, and level VIa. Photon VMAT or intensity-modulated proton therapy was permitted.
  • The prespecified primary endpoint was met, with no elective out-of-field contralateral nodal failures. Across 1,552 person-months at risk, no contralateral failures were observed, giving an estimated upper one-sided 95% confidence limit of 2.7% for the two-year failure rate (p<0.001 for the protocol-defined comparison). Two-year overall survival was 92.2% (95% CI 88.5–95.9%), progression-free survival 86.2% (95% CI 81.4–91.0%), and locoregional control 97.9% (95% CI 95.8–100%). These results establish favorable outcomes within the treated cohort, not equivalence to standard elective coverage.
  • Reduced nodal volumes significantly lowered contralateral parotid exposure in paired planning comparisons. Among the first 20 patients, SAVER reduced mean contralateral parotid dose from 18.3 to 14.1 Gy (p=0.001), an absolute reduction of 4.2 Gy, while parotid V30Gy declined from 20.8% to 11.6% (p=0.003). Mean oral cavity dose was unchanged at 23.8 Gy in both approaches (p=0.991). These dosimetric improvements were demonstrated using paired plans, but their clinical effect on xerostomia was not directly tested against a conventional-volume treatment arm.
  • Acute toxicity remained clinically relevant despite elective volume reduction. Thirteen patients (25.0%) experienced grade ≥3 acute toxicity, including grade 3 dysphagia in 7.7%, oral mucositis in 7.7%, and anorexia in 11.5%. Eight patients (15.4%) required gastrostomy tubes during or immediately after treatment, all removed by six months. No grade ≥3 late adverse events were reported. However, patient-reported severe or very severe dry mouth occurred in 50.0%, and severe swallowing symptoms in 32.7%, demonstrating substantial symptom burden despite the favorable clinician-graded outcomes.
  • The study supports further volume-de-escalation research but cannot establish long-term comparative safety. Swallowing scores declined initially and subsequently recovered toward baseline, whereas patient-reported dry mouth did not fully recover during follow-up. The trial included definitive and postoperative treatment, photon and proton modalities, and nonrandomized patient selection. With only 52 treated patients, no standard-volume control group, and incomplete two-year follow-up for some participants, rare contralateral failures and differences in late xerostomia remain uncertain.

CLINICAL TAKEAWAY

Selective reduction of elective contralateral nodal volumes achieved excellent regional control while significantly lowering contralateral parotid dose in selected patients with HPV-positive oropharyngeal cancer. SAVER offers a promising alternative approach to treatment-volume de-escalation without reducing the prescribed elective dose. However, larger comparative studies and longer follow-up are required before replacing standard contralateral nodal contouring recommendations.

SOURCE

International Journal of Radiation Oncology, Biology, Physics

Browse more research Suggest a correction